Germline Pharmacogenetics of Tamoxifen Response: Have We Learned Enough?
Authors:
- 20 November 2007
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (33) , 5147-5149
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 GenotypesJournal of Clinical Oncology, 2007
- The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifenBreast Cancer Research and Treatment, 2006
- Polymorphism in the CYP2D6 Tamoxifen-Metabolizing Gene Influences Clinical Effect but Not Hot Flashes: Data From the Italian Tamoxifen TrialJournal of Clinical Oncology, 2006
- Endoxifen, a Secondary Metabolite of Tamoxifen, and 4-OH-Tamoxifen Induce Similar Changes in Global Gene Expression Patterns in MCF-7 Breast Cancer CellsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Pharmacogenetics of Tamoxifen Biotransformation Is Associated With Clinical Outcomes of Efficacy and Hot FlashesJournal of Clinical Oncology, 2005
- Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patientsBreast Cancer Research and Treatment, 2005
- CYP2D6 Genotype, Antidepressant Use, and Tamoxifen Metabolism During Adjuvant Breast Cancer TreatmentJNCI: Journal of the National Cancer Institute, 2005
- Active Tamoxifen Metabolite Plasma Concentrations After Coadministration of Tamoxifen and the Selective Serotonin Reuptake Inhibitor ParoxetineJNCI: Journal of the National Cancer Institute, 2003
- Metabolites of tamoxifen in animals and man: Identification, pharmacology, and significanceBreast Cancer Research and Treatment, 1982
- Tamoxifen antiestrogens. A comparison of the activity, pharmacokinetics, and metabolic activation of the cis and trans isomers of tamoxifenThe Journal of Steroid Biochemistry and Molecular Biology, 1982